Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

2020105 citationsJournal Articlehybrid Open Access

Authors

Runze Shang · The 180th Hospital of PLA

Xinhua Song · University of California, San Francisco

Pan Wang · University of California, San Francisco

Yi Zhou · University of California, San Francisco

Xinjun Lu · University of California, San Francisco

Jingxiao Wang · Beijing University of Chinese Medicine

Meng Xu

Abstract

c-MET/ERK/p21/PKM2 cascade and VEGFR2-induced angiogenesis are the primary targets of cabozantinib in HCC treatment. Combination therapies with cabozantinib and mTOR inhibitors may be effective against human HCC.

Topics & Keywords

Cancer Mechanisms and Therapy Hepatocellular Carcinoma Treatment and Prognosis Liver physiology and pathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gut

Volume 70, Issue 9, pp. 1746-1757

DOI: 10.1136/gutjnl-2020-320716

Field-Weighted Citation Impact: 9.71